SCHEMBL25918360

SCHEMBL25918360

Cc1cc(OCCOC2CCCCO2)ccn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 1/20 0.49
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.43
CHEK1 O14757 1/20 0.37
LNPEP Q9UIQ6 1/20 0.36
TGFBR1 P36897 2/20 0.34
TGFBR2 P37173 1/20 0.34
DHFR P00374 1/20 0.34
P2RX3 P56373 4/20 0.33
MET P08581 2/20 0.33
MAOA P21397 1/20 0.32
MAOB P27338 1/20 0.32
KCNH2 Q12809 1/20 0.32
HRH3 Q9Y5N1 1/20 0.32
ALDH1A1 P00352 1/20 0.32
CASP1 P29466 1/20 0.32
CASP7 P55210 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30225192 0.85 KDM4C (0.49) KDM4CNPC1RAB9AMEN1KMT2A
SCHEMBL30225190 0.85 KDM4C (0.49) KDM4CNPC1RAB9AMEN1KMT2A
SCHEMBL23975779 0.85 KDM4C (0.49) KDM4CNPC1RAB9AMEN1KMT2A
SCHEMBL17769914 0.85 KDM4C (0.49) KDM4CNPC1RAB9AMEN1KMT2A
SCHEMBL30225322 0.84 KDM4C (0.46) KDM4CNPC1RAB9AMEN1KMT2A
SCHEMBL9827131 0.82 DHFR (0.44) KDM4CNPC1RAB9AMEN1KMT2A
SCHEMBL31428456 0.82 NPC1 (0.53) KDM4CNPC1RAB9AMEN1KMT2A
SCHEMBL25918031 0.82 KDM4C (0.52) KDM4CNPC1RAB9AMEN1KMT2A
SCHEMBL12409080 0.81 KDM4C (0.50) KDM4CNPC1RAB9AMEN1KMT2A
SCHEMBL171304 0.80 MEN1 (0.59) KDM4CNPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11746100-B2 Cycloalkyl pyrimidines as ferroportin inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-09-05 US disclosed
US-20230226074-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2023-07-20 US disclosed
US-20230159553-A1 THIENO PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226074-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS SLC40A1, HAMP, SLC19A1 KDM4C 4507/4885NPC1 897/4885RAB9A 2710/4885
US-20230159553-A1 THIENO PYRIMIDINES AS FERROPORTIN INHIBITORS SLC40A1, HAMP, SLC19A1 KDM4C 4515/4885NPC1 965/4885RAB9A 2601/4885
US-11746100-B2 Cycloalkyl pyrimidines as ferroportin inhibitors HAMP, SLC40A1, FANCI KDM4C 4818/4885NPC1 389/4885RAB9A 2831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.